Pliant Therapeutics Shares it 52-Week Low
Hosted on MSN1h
Pliant Therapeutics Reports Q4 2024 Results and UpdatesPliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...
As previously reported, Stifel analyst Alex Thompson downgraded Pliant Therapeutics (PLRX) to Hold from Buy with a price target of $3, down ...
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...
Norms recognized for decades in Washington by both parties no longer appear to apply to the Trump White House, former ...
TVNewsCheck on MSN16h
NAB Show: Pliant To Intro Dual Listen To CrewCom CB2Pliant Technologies’ CrewCom CB2 Professional Wireless Intercom system is a full-duplex, install-friendly and feature-packed solution for small to mid-level applications requiring a reliable, great ...
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
CrewCom CB2 is a full-duplex, install-friendly and feature-packed solution for small to mid-level applications requiring a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback